Targeted investment needed to end rheumatic heart disease in Africa.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Acute pharyngitis in children and adults: descriptive comparison of current recommendations from national and international guidelines and future perspectives.European journal of pediatrics · 2023
   Review
2. Tertiary prevention and treatment of rheumatic heart disease: a National Heart, Lung, and Blood Institute working group summary.BMJ global health · 2023
   Review
3. Global, Regional, and National Advances Toward the Management of Rheumatic Heart Disease Based on the Global Burden of Disease Study 2019.Journal of the American Heart Association · 2023
   Article
4. Rheumatic Heart Disease in Pregnancy: New Strategies for an Old Disease?Global heart · 2021
   Review

Corrections and comments

• Comment on
  An investment case for the prevention and management of rheumatic heart disease in the African Union 2021-30: a modelling study.2021

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as